Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2024-06-28 AGM Information
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Zwyczajne Walne Zgromadzenie Pure Biologics S.A. z dnia 28.06.2024 - treść uchwał
AGM Information Classification · 100% confidence The document text consists of multiple numbered resolutions ("Uchwała Nr X/2024") passed by the "Zwyczajne Walne Zgromadzenie" (Ordinary General Meeting) of Pure Biologics Spółka Akcyjna on June 28, 2024. These resolutions cover procedural matters (electing a chairman, adopting the agenda) and substantive items typically addressed at an AGM, such as approving the Management Board's report, the Supervisory Board's report, the financial statements for 2023, and voting on dividend policy/loss coverage. The content explicitly details the proceedings and outcomes of a General Meeting, which aligns perfectly with the definition of AGM Information.
2024-06-28 Polish
Treść uchwał podjętych oraz uchwały niepoddanej pod głosowanie przez Zwyczajne Walne Zgromadzenie Pure Biologics S.A. 28 czerwca 2024 r. - Content (PL)
AGM Information Classification · 98% confidence The document text is in Polish and discusses the resolutions ('uchwał') adopted by the Ordinary General Meeting ('Zwyczajne Walne Zgromadzenie' or 'ZWZ') held on June 28, 2024. It details the voting results (votes for, against, abstained) and mentions that one resolution (point 11) was not voted upon due to lack of quorum, citing a specific article of the Commercial Companies Code (art. 431 § 3a.). This content directly relates to the official results and proceedings of a shareholder meeting. This aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (AGM-R or DVA). Since it explicitly details the results of the resolutions passed at the AGM, AGM-R (AGM Information/Results) is the most precise fit, although DVA is also highly relevant. Given the context of reporting the resolutions and voting outcomes of the AGM, AGM-R is selected as the primary category for AGM-related outcomes.
2024-06-28 Polish
Wykonanie praw z warrantów serii B i objęcie akcji serii K Spółki - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document text describes a specific corporate action where an investor exercised subscription warrants to acquire new shares of the company. This involves a change in capital structure and the issuance of new shares based on prior agreements (warrants). This action directly relates to the issuance of new shares or changes in the capital base. The most fitting category is 'Share Issue/Capital Change' (SHA), as it details the subscription and issuance of 154,272 new shares. It is not a general financing update (CAP) but a specific execution of a capital instrument.
2024-06-25 Polish
Złożenie wniosku eIND do FDA w projekcie PB003G - Content (PL)
Regulatory Filings Classification · 95% confidence The document text discusses the submission of an eIND (exploratory Investigational New Drug) application to the FDA for a drug candidate (PBA-0111) to initiate Phase 0 clinical trials. It details the drug's mechanism of action, preclinical study results (tumor growth inhibition in mice, safety profile), and the agreement with Presage Biosciences for conducting the trial. This content relates to significant regulatory and clinical development milestones for a drug candidate. While it is a report of an event, it is not a comprehensive Annual Report (10-K), an Interim Report (IR), or a general Earnings Release (ER). It is a specific announcement concerning regulatory/clinical progress. Given the options, this type of detailed update on a key development milestone, often filed as a current report (raport bieżący in Polish context), fits best under the general 'Regulatory Filings' category (RNS) as it is a specific, material event disclosure that doesn't fit the other specialized categories like M&A (TAR) or Capital Change (CAP). It is not a presentation (IP) or a transcript (CT).
2024-06-12 Polish
Sprawozdanie Rady Nadzorczej Spółki z działalności za rok 2023
Board/Management Information Classification · 99% confidence The document is titled "SPRAWOZDANIE RADY NADZORCZEJ Z DZIAŁALNOŚCI ZA ROK 2023" (Supervisory Board Report on Activities for the Year 2023) and is dated May 27, 2024. It details the Supervisory Board's assessment of the annual financial statements, the Management Board's activity report, the proposal for covering the net loss for 2023, and an evaluation of the consolidated situation and internal control systems for 2023. This content strongly aligns with the requirements for a comprehensive annual review document, often associated with the Annual Report (10-K) process, but specifically focuses on the oversight and governance aspects performed by the Supervisory Board. However, none of the provided codes perfectly match a 'Supervisory Board Report' or 'Corporate Governance Report' based on the Polish context, except for Governance Information (CGR) or potentially Audit Report (AR) due to the extensive review of financial statements and internal controls. Given the document's structure, which covers the review of financial statements, management activities, loss coverage proposal, and internal controls/governance practices for the entire year 2023, it functions as a key governance document accompanying the annual filings. Comparing the options: - 10-K: This is the full Annual Report, which this document reviews/accompanies, but this specific document is the Supervisory Board's report on that activity. - AR (Audit Report / Information): This covers standalone audit reports. This document includes the audit review but is much broader. - CGR (Governance Information): This covers internal rules, board structure, and governance practices. The document heavily covers governance (internal controls, risk management, board structure assessment, compliance with Good Practices). Since the document is a formal report from the Supervisory Board detailing its oversight functions, including the review of financial statements, management activities, and corporate governance compliance (including risk management and internal controls) for the full fiscal year 2023, it fits best under Governance Information (CGR), as it is a detailed report on corporate governance practices and oversight. The document is a full report, not an announcement of a report (ruling 2 does not apply). The length (40k chars) confirms it is a substantial report.
2024-05-31 Polish
Projekty uchwał ZWZ Spółki_28.06.2024
AGM Information Classification · 100% confidence The document consists entirely of resolutions ("UCHWAŁA") passed by the "ZWYCZAJNE WALNE ZGROMADZENIE" (Annual General Meeting - AGM) of Pure Biologics S.A. on June 28, 2024. The resolutions cover procedural matters, approval of the 2023 management and financial reports, allocation of loss, continuation of the company, granting of discharge (absolutorium) to management and supervisory board members for 2023, and amendments to a prior resolution regarding a capital increase. Documents detailing the proceedings and resolutions of an Annual General Meeting fall directly under the definition of AGM Information.
2024-05-31 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.